Novartis AG - Product Pipeline Review - 2015

  • ID: 3338396
  • Company Profile
  • 484 pages
  • Global Markets Direct
  • Novartis AG
1 of 3
Novartis AG - Product Pipeline Review - 2015

Summary

This, ‘Novartis AG - Product Pipeline Review - 2015’, provides an overview of the Novartis AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Novartis AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Novartis AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Novartis AG’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Novartis AG’s pipeline products

Reasons to buy

- Evaluate Novartis AG’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Novartis AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Novartis AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Novartis AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Novartis AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Novartis AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 3
List of Tables
List of Figures
Novartis AG Snapshot
Novartis AG Overview
Key Information
Key Facts
Novartis AG - Research and Development Overview
Key Therapeutic Areas
Novartis AG - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Novartis AG - Pipeline Products Glance
Novartis AG - Late Stage Pipeline Products
Novartis AG - Clinical Stage Pipeline Products
Novartis AG - Early Stage Pipeline Products
Novartis AG - Unknown Stage Pipeline Products
Novartis AG - Drug Profiles
(indacaterol maleate + glycopyrrolate)
(sacubitril + valsartan)
eltrombopag olamine
erismodegib
EXE-844
glycopyrrolate
haemophilus influenzae [serotype B] vaccine
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine
omalizumab
panobinostat
ruxolitinib phosphate
serelaxin
trametinib dimethyl sulfoxide
imatinib mesylate
pazopanib hydrochloride
(vildagliptin + metformin hydrochloride)
aliskiren fumarate
bimagrumab
buparlisib hydrochloride
canakinumab
ceritinib
dabrafenib mesylate
everolimus
EXE-844b
fingolimod hydrochloride
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine
midostaurin
nilotinib
ofatumumab
osilodrostat
oxytocin
pasireotide
pasireotide LAR
pradigastat sodium
ranibizumab
ribociclib
seasonal influenza (quadrivalent) vaccine
secukinumab
siponimod
zoledronic acid
(VAK-694 + dectrekumab)
aldesleukin
alpelisib
AQW-051
BCT-197
BGS-649
BHQ-880
BPS-804
BVS-857
CAD-106
capmatinib
CDZ-173
CFZ-533
cipargamin
CJM-112
dectrekumab
EGF-816
FCR-001
fevipiprant
GSK-2285921
HSC-835
infigratinib
influenza [strain H5N1] vaccine
KAF-156
KRP-203
LCL-161
LFF-269
LFG-316
LFX-453
ligelizumab
LIK-066
LJM-716
LMI-070
mavoglurant
MCS-110
NOV-3
octreotide acetate long acting
QAL-964
QBM-076
QBW-251
seasonal influenza (trivalent) vaccine
selurampanel
tisagenlecleucel-T
VAY-736
BPR-277
BZF-961
CFG-920
CGF-166
CLR-457
CSJ-148
FGF-401
HDM-201
LAG-525
lapatinib ditosylate
LEZ-763
LFA-102
LGK-974
PDR-001
PIM-447
RAF-265
sotrastaurin acetate
ABL-001
Cell Therapy to Target c-Met for Cancer
Cell Therapy to Target EGFR for Glioblastoma
CGM-097
huCART19
IDH-305
influenza [strain A/H3N2] (monovalent) vaccine
influenza [strain H7N9] (monovalent) vaccine
LEQ-506
LHW-090
LML-134
LOP-628
MesoCART
NOV-10
NOV-7
NOV-8
NOV-9
octreotide acetate LAR
PCA-062
QCC-374
TAP-311
Antibody to Inhibit PD-L1 for Cancer
Antibody to Inhibit TIM-3 for Cancer
AUSRM-057
BQS-481
BVB-808
CART-123
Cell Therapy Program for Cancer
Cell Therapy to Target 5T4 for Oncology
Cell Therapy to Target GD2 for Neuroblastoma
cosyntropin ER
ESK-1
GNFPf-5069
HG-78501
IMP-701
Kartogenin
KR-22809
LCZ-960
LGB-321
LQN-725
Monoclonal Antibody Conjugated 3 for Cancer
Monoclonal Antibody to Inhibit CXCR2 for Respiratory Diseases
NIBR-0213
NITD-349
NITD-916
NVPQBE-170
NVPTNKS-656
Small Molecule to Activate Nurr1 for Multiple Sclerosis
Small Molecule to Agonize GPR119 for Type 2 Diabetes
Small Molecule to Agonize GPR39 for Type 2 Diabetes
Small Molecule to Inhibit LRRK2 for Parkinsons Disease
Small Molecule to Inhibit OX2R for Insomnia
Small Molecules to Antagonize CSF1R for Cancer and Osteolysis
Small Molecules to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes
Small Molecules to Inhibit Pan-RAF Kinase for Oncology
Antibodies to Inhibit CTLA4 and PD-1 for Cancer
ESBA-903 SR
LJH-685
Small Molecule to Agonize Adrenergic Beta-2 Receptor for COPD
Small Molecules 1 for Undisclosed Indication
Small Molecules 2 for Undisclosed Indication
Small Molecules for Malaria
Small Molecules for Rhinovirus Infection
Small Molecules for Tuberculosis
Small Molecules to Inhibit Acetyl-CoA Carboxylase for Metabolic, Cardiovascular and Infections
Small Molecules to Inhibit CFTR for Secretory Diarrhea
Small Molecules to Inhibit PI4KIIIbeta for HCV
Small Molecules to Inhibit Renin for Hypertension
Small Molecules for Mycobacterium Tuberculosis
Novartis AG - Pipeline Analysis
Novartis AG - Pipeline Products by Target
Novartis AG - Pipeline Products by Route of Administration
Novartis AG - Pipeline Products by Molecule Type
Novartis AG - Pipeline Products by Mechanism of Action
Novartis AG - Recent Pipeline Updates
Novartis AG - Dormant Projects
Novartis AG - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Novartis AG - Company Statement
Novartis AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Novartis AG, Key Information
Novartis AG, Key Facts
Novartis AG - Pipeline by Indication, 2015
Novartis AG - Pipeline by Stage of Development, 2015
Novartis AG - Monotherapy Products in Pipeline, 2015
Novartis AG - Combination Treatment Modalities in Pipeline, 2015
Novartis AG - Partnered Products in Pipeline, 2015
Novartis AG - Partnered Products/ Combination Treatment Modalities, 2015
Novartis AG - Out-Licensed Products in Pipeline, 2015
Novartis AG - Out-Licensed Products/ Combination Treatment Modalities, 2015
Novartis AG - Pre-Registration, 2015
Novartis AG - Filing rejected/Withdrawn, 2015
Novartis AG - Phase III, 2015
Novartis AG - Phase II, 2015
Novartis AG - Phase I, 2015
Novartis AG - Preclinical, 2015
Novartis AG - Discovery, 2015
Novartis AG - Unknown, 2015
Novartis AG - Pipeline by Target, 2015
Novartis AG - Pipeline by Route of Administration, 2015
Novartis AG - Pipeline by Molecule Type, 2015
Novartis AG - Pipeline Products by Mechanism of Action, 2015
Novartis AG - Recent Pipeline Updates, 2015
Novartis AG - Dormant Developmental Projects,2015
Novartis AG - Discontinued Pipeline Products, 2015
Novartis AG, Subsidiaries

List of Figures
Novartis AG - Pipeline by Top 10 Indication, 2015
Novartis AG - Pipeline by Stage of Development, 2015
Novartis AG - Monotherapy Products in Pipeline, 2015
Novartis AG - Combination Treatment Modalities in Pipeline, 2015
Novartis AG - Partnered Products in Pipeline, 2015
Novartis AG - Out-Licensed Products in Pipeline, 2015
Novartis AG - Pipeline by Top 10 Target, 2015
Novartis AG - Pipeline by Top 10 Route of Administration, 2015
Novartis AG - Pipeline by Top 10 Molecule Type, 2015
Novartis AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll